Key Highlights

  • Biohaven Ltd. (NYSE: BHVN) announced Bruce Car, Ph.D. Will retire as Chief Scientific Officer on July 13, 2026, transitioning to a part-time Chief Innovation Officer role.
  • Car’s salary will be reduced by 50% to reflect his new work schedule.
  • Car will continue as an executive officer, focusing on scientific initiatives and external collaborations.

Leadership Transition Announced

Biohaven Ltd. (NYSE: BHVN) revealed a major leadership shift, with Bruce Car, Ph.D. Stepping down as Chief Scientific Officer. The change takes effect July 13, 2026, as part of a mutual agreement between Car and the biopharmaceutical company. Car will remain with Biohaven in a newly created part-time position.

New Role for Car

Car will assume the title of Chief Innovation Officer, where he will drive scientific initiatives and external partnerships. His responsibilities include leading multiple assets under Biohaven’s collaboration with Bexorg, Inc. The transition reflects a strategic realignment of executive focus within the company.

Salary Adjustment Details

In connection with his move to a part-time schedule, Car’s salary will be reduced by 50%. The adjustment aligns compensation with his revised work commitments. Pirman will oversee Biohaven’s internal drug-discovery organization and research programs.

The promotion underscores the company’s commitment to advancing its pipeline.

Regulatory Filing Confirms Changes

The leadership updates were disclosed in a regulatory filing dated July 9, 2026. The document confirmed Car’s continued status as an executive officer. No related-party transactions requiring disclosure were identified under applicable securities rules.

Focus on External Collaborations

Car’s new role emphasizes Biohaven’s push to strengthen external partnerships. His work with Bexorg, Inc. Will remain a priority as the company seeks to expand its therapeutic portfolio. The shift signals a broader strategy to balance internal and collaborative innovation.

Executive Continuity Maintained

Despite the leadership change, Biohaven’s executive structure remains stable. Car’s ongoing involvement as an officer ensures continuity in key scientific and strategic initiatives. The company has not announced further adjustments to its leadership team.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.